CARsgen Warning Letter Notes Company Paused Manufacture Following 483

Following an FDA inspection of its North Carolina facility that found inadequate personnel training, non-implementation of quality control procedures and scuttle fly larva on employee clothing, Shanghai-based CARsgen Therapeutics has…

Continue ReadingCARsgen Warning Letter Notes Company Paused Manufacture Following 483

Liveyon CEO Pleads Guilty to Felony Distribution of Unapproved Stem Cell Drug

The CEO that founded Liveyon, a manufacturer and distributor of stem cell-derived products tied to bacterial infections requiring hospitalization, has plead guilty to felony distribution of unapproved drug products, the…

Continue ReadingLiveyon CEO Pleads Guilty to Felony Distribution of Unapproved Stem Cell Drug

Eugia Pharma Specialties Warning Letter Cites Incomplete Test Data, Inaccurate Records

Failure to conduct complete testing on sterile injectables, falsified monitoring records of areas used for aseptic filling lines as well as falsified cleaning records are among the serious lapses documented…

Continue ReadingEugia Pharma Specialties Warning Letter Cites Incomplete Test Data, Inaccurate Records

FDA Decision on Regeneron’s Linvoseltamab Held Back by Third-Party Manufacturer

Regeneron Pharmaceuticals has confirmed that the FDA will not make a decision on approving its investigational multiple myeloma drug linvoseltamab for at least the next few months, citing problems encountered…

Continue ReadingFDA Decision on Regeneron’s Linvoseltamab Held Back by Third-Party Manufacturer